Announced Tue, 28 Apr · 19:41 IST
Astec LifeSciences reports FY26 results; losses narrow, revenue up ~17%
Compliance View source PDF
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-4.7%1-day move
₹728.90
prior close
₹733.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.1-0.7-2.1-2.3-4.7-1.2-6.2-4.0-1.6-4.5+1.9+5.2-2.0—
Up moveDown movePending
AI summary
Astec LifeSciences (Godrej group) reported audited FY26 results. Consolidated revenue rose to Rs 45,313 lakh from Rs 38,686 lakh in FY25. Net loss narrowed to Rs 8,101 lakh from Rs 13,481 lakh. Q4 FY26 standalone loss was Rs 775 lakh vs Rs 1,608 lakh YoY. Debt-equity ratio improved to 1.15 from 2.36, supported by a July 2025 rights issue (26.7 lakh shares allotted at Rs 890 each). Labour Code impact of Rs 209 lakh shown as exceptional items. Auditors gave an unmodified opinion.
Likely market impact
Narrowing losses, ~17% revenue growth and stronger balance sheet are positives, though company remains in the red at the bottom line.